CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
CASI Pharmaceuticals Update: CASI Pharmaceuticals, Inc. has reported a material development regarding its dispute with Juventas through a current report on Form 6-K, which can be accessed via the SEC website.
Company Overview and Risks: CASI is focused on developing innovative therapeutics in China and globally, but faces various risks including capital raising challenges, potential delisting from Nasdaq, and uncertainties in clinical trials and regulatory approvals.
Trade with 70% Backtested Accuracy
Analyst Views on CASI
About CASI
About the author
Dayforce Shares Surge Approximately 21%; Check Out 20 Stocks Making Moves in Premarket Trading
Dayforce Inc Acquisition Talks: Shares of Dayforce Inc rose 21.4% in pre-market trading following reports that Thoma Bravo is in discussions to acquire the company.
Notable Gainers: Other stocks experiencing significant gains include Propanc Biopharma (up 253%), Adaptimmune Therapeutics (up 70.3%), and DIH Holding US (up 43.4%).
Significant Losers: TPI Composites saw a drastic decline of 51.1%, while SRx Health Solutions and Empery Digital also faced notable drops of 25.8% and 22.2%, respectively.
Market Overview: The article highlights various stocks' movements in pre-market trading, showcasing both substantial gainers and losers, reflecting market volatility.
Premarket Stock Movements: PPCB, BTAI, TNXP, DAY, TPIC, and Other Notable Gainers and Losers
Premarket Trading Activity: Notable activity is observed in premarket trading as of 6.50 a.m. ET on Monday, indicating potential opportunities before the market opens.
Importance for Traders: Premarket trading allows active traders to identify possible breakouts, reversals, or price swings, making it crucial for analyzing momentum heading into the regular session.
Stocks Performance: Some stocks are showing significant percentage increases while others are experiencing notable declines during Monday's premarket session.
Author's Perspective: The views expressed in the article reflect the author's opinions and do not necessarily represent those of Nasdaq, Inc.
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Earnings Performance: Xenetic Biosciences reported a quarterly loss of $0.45 per share, better than the expected loss of $0.64, marking a 29.69% earnings surprise; however, revenues of $0.59 million fell short of estimates by 7.81%.
Market Outlook: The company's stock has underperformed with a 30.8% decline this year, and its future performance will depend on management's commentary and revisions to earnings estimates, currently rated as Zacks Rank #3 (Hold).
HC Wainwright & Co. Reiterates Buy on CASI Pharmaceuticals, Maintains $4 Price Target
Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.
CASI Pharma Receives New $20 Mln Buyout Proposal For China Unit And Drug Rights
CASI Pharmaceuticals Proposal: CASI Pharmaceuticals Inc. announced that its Special Committee received an updated non-binding proposal from CEO Dr. Wei-Wu He to acquire the company's operations in China for $20 million, which includes assuming $20 million in debt and rights to certain products in Asia.
Evaluation of Proposal: The board has formed a Special Committee to evaluate this proposal and other strategic options, emphasizing that no decisions have been made yet and there is no guarantee that a definitive agreement will be reached.
Casi Pharmaceuticals files $200M mixed securities shelf
Casi Pharmaceuticals Filing: Casi Pharmaceuticals (CASI) has filed a $200 million mixed securities shelf registration, allowing them to raise capital through various types of securities.
Recent Performance and News: The company is currently facing challenges, including a license termination dispute regarding Evomela® and mixed financial results for Q3 2024, with an EPS of 55 cents compared to a loss of 35 cents last year.
Dayforce Shares Surge Approximately 21%; Check Out 20 Stocks Making Moves in Premarket Trading
Dayforce Inc Acquisition Talks: Shares of Dayforce Inc rose 21.4% in pre-market trading following reports that Thoma Bravo is in discussions to acquire the company.
Notable Gainers: Other stocks experiencing significant gains include Propanc Biopharma (up 253%), Adaptimmune Therapeutics (up 70.3%), and DIH Holding US (up 43.4%).
Significant Losers: TPI Composites saw a drastic decline of 51.1%, while SRx Health Solutions and Empery Digital also faced notable drops of 25.8% and 22.2%, respectively.
Market Overview: The article highlights various stocks' movements in pre-market trading, showcasing both substantial gainers and losers, reflecting market volatility.
Premarket Stock Movements: PPCB, BTAI, TNXP, DAY, TPIC, and Other Notable Gainers and Losers
Premarket Trading Activity: Notable activity is observed in premarket trading as of 6.50 a.m. ET on Monday, indicating potential opportunities before the market opens.
Importance for Traders: Premarket trading allows active traders to identify possible breakouts, reversals, or price swings, making it crucial for analyzing momentum heading into the regular session.
Stocks Performance: Some stocks are showing significant percentage increases while others are experiencing notable declines during Monday's premarket session.
Author's Perspective: The views expressed in the article reflect the author's opinions and do not necessarily represent those of Nasdaq, Inc.
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Earnings Performance: Xenetic Biosciences reported a quarterly loss of $0.45 per share, better than the expected loss of $0.64, marking a 29.69% earnings surprise; however, revenues of $0.59 million fell short of estimates by 7.81%.
Market Outlook: The company's stock has underperformed with a 30.8% decline this year, and its future performance will depend on management's commentary and revisions to earnings estimates, currently rated as Zacks Rank #3 (Hold).
HC Wainwright & Co. Reiterates Buy on CASI Pharmaceuticals, Maintains $4 Price Target
Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.
CASI Pharma Receives New $20 Mln Buyout Proposal For China Unit And Drug Rights
CASI Pharmaceuticals Proposal: CASI Pharmaceuticals Inc. announced that its Special Committee received an updated non-binding proposal from CEO Dr. Wei-Wu He to acquire the company's operations in China for $20 million, which includes assuming $20 million in debt and rights to certain products in Asia.
Evaluation of Proposal: The board has formed a Special Committee to evaluate this proposal and other strategic options, emphasizing that no decisions have been made yet and there is no guarantee that a definitive agreement will be reached.
Casi Pharmaceuticals files $200M mixed securities shelf
Casi Pharmaceuticals Filing: Casi Pharmaceuticals (CASI) has filed a $200 million mixed securities shelf registration, allowing them to raise capital through various types of securities.
Recent Performance and News: The company is currently facing challenges, including a license termination dispute regarding Evomela® and mixed financial results for Q3 2024, with an EPS of 55 cents compared to a loss of 35 cents last year.
